Opportunity Information: Apply for PA 09 167
Apply for PA 09 167
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Apr 17, 2009 and posted on Apr 17, 2009.
- Applicants must submit their applications by May 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Public and State controlled institutions of higher education State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21) (PA-09-167) is a National Institutes of Health grant opportunity led by the National Cancer Institute (NCI) together with the National Institute of Nursing Research (NINR). It was designed to support exploratory and early-stage research on complementary approaches used alongside conventional cancer care. The central aim is to generate strong preliminary evidence, especially in humans, that can justify larger, definitive follow-on studies such as an NIH R01 focused on efficacy and clinical impact.
The scope is broad and spans basic, preclinical, and clinical investigations, as long as the work is clearly tied to cancer prevention, diagnosis, treatment, or the management of symptoms and side effects that result from standard cancer therapies. In practice, that includes studies looking at how complementary interventions might reduce pain, fatigue, nausea, anxiety, sleep disruption, neuropathy, or other common treatment-related burdens, as well as projects that test whether certain complementary strategies can improve patient function, adherence to therapy, or overall quality of life during and after treatment.
A major emphasis of the FOA is on innovation and the use of emerging technologies or novel applications of existing tools. It explicitly encourages research that identifies and evaluates new therapeutics drawn from Traditional Medical Systems, as recognized by the World Health Organization, which can include systematic exploration of pharmacologically active compounds and biologically plausible mechanisms. It also invites projects that examine whether complementary approaches can improve the therapeutic ratio of anticancer therapies, meaning the balance between benefit and harm, such as by enhancing treatment response, reducing toxicity, or helping patients tolerate standard or investigational regimens more effectively.
The announcement also highlights lifestyle modification research as a priority area. Applicants were encouraged to study interventions like diet, physical activity, and mind-body approaches, not only for symptom management but also for their potential influence on cancer-related outcomes. Examples of outcomes emphasized include response to conventional therapy and survival, indicating interest in clinically meaningful endpoints in addition to patient-reported outcomes and intermediate biomarkers.
This FOA uses the NIH Exploratory/Developmental Research Grant (R21) mechanism, which is typically intended for early, high-potential studies that may involve higher risk but can open up new lines of investigation. It ran in parallel with a companion announcement (PA-09-168) using the NIH R03 small grant mechanism, described as having identical scientific scope but a smaller project scale. The R21 described here had an award ceiling listed at $200,000, and it did not require cost sharing or matching.
Eligibility was intentionally wide, reflecting NIH's interest in reaching diverse research settings and communities. Eligible applicants included public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (other than small businesses), small businesses, state governments, and tribal governments and tribal organizations. The FOA also specifically called out additional eligible groups such as faith-based or community-based organizations, Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), U.S. territories or possessions, and non-U.S. (foreign) entities and regional organizations, along with eligible federal agencies.
Administratively, the opportunity was categorized as a discretionary grant in the health and education activity space and was associated with CFDA numbers 93.395 (Cancer Treatment Research) and 93.361 (Nursing Research). It was posted on April 17, 2009, with a closing date of May 7, 2012, and it was archived on June 7, 2012. The full announcement was available through NIH’s grants guide page, and NIH’s Office of Extramural Research (OER) webmaster contact was provided for access or technical issues.
FAQs: Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21) (PA-09-167)
What is PA-09-167?
PA-09-167 is a National Institutes of Health (NIH) funding opportunity titled "Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21)." It supports exploratory and early-stage research on complementary approaches used alongside conventional cancer care.
Which NIH institutes lead this opportunity?
The opportunity is led by the National Cancer Institute (NCI) together with the National Institute of Nursing Research (NINR).
What is the main purpose of this R21 funding opportunity?
The central aim is to generate strong preliminary evidence, especially in humans, that can justify larger, definitive follow-on studies such as an NIH R01 focused on efficacy and clinical impact.
What kinds of research does the FOA support?
The scope is broad and includes basic, preclinical, and clinical investigations, as long as the project is clearly tied to cancer prevention, diagnosis, treatment, or the management of symptoms and side effects resulting from standard cancer therapies.
Does the FOA require that studies be conducted in humans?
The FOA emphasizes generating strong preliminary evidence, especially in humans. It also allows basic and preclinical work as long as it is clearly linked to cancer-related goals described in the announcement.
What does "complementary approaches" mean in this FOA?
In this context, complementary approaches are interventions used alongside conventional cancer care. The announcement focuses on complementary strategies relevant to prevention, diagnosis, treatment, and symptom/side-effect management during and after standard therapies.
What cancer-related symptoms or side effects are explicitly within scope?
The FOA includes projects that address common burdens associated with cancer therapy such as pain, fatigue, nausea, anxiety, sleep disruption, neuropathy, and other treatment-related symptoms and side effects.
Can projects focus on quality of life and functional outcomes?
Yes. The FOA includes work aimed at improving patient function, adherence to therapy, or overall quality of life during and after treatment.
Is innovation a priority for this announcement?
Yes. A major emphasis is on innovation, including the use of emerging technologies or novel applications of existing tools.
Does the FOA encourage research based on Traditional Medical Systems?
Yes. It explicitly encourages identifying and evaluating new therapeutics drawn from Traditional Medical Systems as recognized by the World Health Organization (WHO), including systematic exploration of pharmacologically active compounds and biologically plausible mechanisms.
Can projects evaluate mechanisms of action?
Yes. The FOA encourages work that explores pharmacologically active compounds and biologically plausible mechanisms, including for therapeutics associated with Traditional Medical Systems.
What does "improving the therapeutic ratio" mean in this FOA?
It refers to improving the balance between benefit and harm in anticancer therapies. The FOA invites projects examining whether complementary approaches can enhance treatment response, reduce toxicity, or help patients tolerate standard or investigational regimens more effectively.
Are lifestyle modification interventions within scope?
Yes. Lifestyle modification is highlighted as a priority area, including interventions such as diet, physical activity, and mind-body approaches.
Are lifestyle interventions limited to symptom management?
No. The FOA notes interest in lifestyle interventions not only for symptom management but also for potential influence on cancer-related outcomes.
What outcomes does the FOA highlight for lifestyle modification research?
Examples emphasized include response to conventional therapy and survival, indicating interest in clinically meaningful endpoints, in addition to patient-reported outcomes and intermediate biomarkers.
What grant mechanism is used?
This FOA uses the NIH Exploratory/Developmental Research Grant (R21) mechanism, which is intended for early, high-potential studies that may involve higher risk but can open new lines of investigation.
Is there a related or companion funding opportunity?
Yes. The announcement ran in parallel with a companion announcement (PA-09-168) using the NIH R03 small grant mechanism. It is described as having identical scientific scope but a smaller project scale.
What is the award ceiling for this R21 opportunity?
The R21 described here had an award ceiling listed at $200,000.
Is cost sharing or matching required?
No. The announcement states that it did not require cost sharing or matching.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); small businesses; state governments; and tribal governments and tribal organizations.
Are community-based and faith-based organizations eligible?
Yes. The FOA specifically includes faith-based or community-based organizations among eligible applicants.
Are minority-serving institutions specifically encouraged or included?
Yes. The FOA specifically calls out eligibility for Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and Tribally Controlled Colleges and Universities (TCCUs).
Are U.S. territories or possessions eligible?
Yes. The FOA specifically includes U.S. territories or possessions among eligible entities.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA includes non-U.S. (foreign) entities and regional organizations as eligible applicants.
Are federal agencies eligible?
Yes. The FOA indicates that eligible federal agencies are included.
How is this opportunity categorized administratively?
It is categorized as a discretionary grant in the health and education activity space.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.395 (Cancer Treatment Research) and CFDA 93.361 (Nursing Research).
When was the opportunity posted?
It was posted on April 17, 2009.
What was the closing date?
The closing date was May 7, 2012.
Is this funding opportunity still active?
No. It was archived on June 7, 2012.
Where could applicants access the full announcement?
The full announcement was available through NIH's grants guide page.
Who was listed for access or technical issues?
NIH's Office of Extramural Research (OER) webmaster contact was provided for access or technical issues related to the announcement.
Browse more opportunities from the same category: Education Health
Next opportunity: Community Services Block Grant (CSBG)/Rural Community Development Facilities Program (RCDAP)/ Homeland Security Program Water and Wastewater Treatment Systems Safety and Security Training and Technical Assistance Project
Previous opportunity: Renal Function and Chronic Kidney Disease in Aging (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 167
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 167) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R03) Apply for PA 09 168 Funding Number: PA 09 168 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program (U10) Apply for RFA CA 09 023 Funding Number: RFA CA 09 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Renewal of Centers of Biomedical Research Excellence (COBRE)P20 Apply for PAR 09 180 Funding Number: PAR 09 180 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Centers of Biomedical Research Excellence (COBRE) Phase III Transitional Centers P30 Apply for RFA RR 09 005 Funding Number: RFA RR 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Community Clinical Oncology Program (U10) Apply for RFA CA 09 022 Funding Number: RFA CA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technologies and Software to Support Integrative Cancer Biology Research (SBIR) R43/R44 Apply for PA 09 188 Funding Number: PA 09 188 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology Development for the Detection and Evaluation of Chemical and Biological Carcinogens (SBIR) R43/R44 Apply for PA 09 187 Funding Number: PA 09 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology for the Detection and Characterization of Low Abundance Proteins, Peptides, or micro RNAs (SBIR) R43/R44 Apply for PA 09 189 Funding Number: PA 09 189 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Translational Neuroscience and Adolescent Drug Abuse Treatment (R21) Apply for RFA DA 10 003 Funding Number: RFA DA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaborations on HIV/AIDS and Drug Use (R01) Apply for RFA DA 10 008 Funding Number: RFA DA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs)(U54) Apply for RFA CA 09 012 Funding Number: RFA CA 09 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,200,000 |
| Cancer Nanotechnology Platform Partnerships (U01) Apply for RFA CA 09 013 Funding Number: RFA CA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 09 197 Funding Number: PA 09 197 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 09 198 Funding Number: PA 09 198 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R21) Apply for PA 09 200 Funding Number: PA 09 200 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R01) Apply for PA 09 199 Funding Number: PA 09 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The National Drug Abuse Treatment Clinical Trials Network (U10) Apply for RFA DA 10 009 Funding Number: RFA DA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R21) Apply for PA 09 191 Funding Number: PA 09 191 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R01) Apply for PA 09 190 Funding Number: PA 09 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Apply for PAR 09 162 Funding Number: PAR 09 162 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 167", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.